Phylogica Ltd. said Genentech has extended its exclusivity period for the research collaboration and license agreement to discover novel antibiotics utilizing Phylogica’s Phylomer drug discovery platform, including its proprietary cell penetrating peptide discovery technology.
A member of the Roche Group, Phylogica is a public Australian drug discovery company. Genentech is a member of the Roche Group.
